blood vessel inflammation News
-
Diesel Exhaust + Cholesterol = Cardiovascular Disease
LOS ANGELES, California, July 26, 2007 (ENS) - Exposure to a combination of diesel exhaust and high blood cholesterol increases the risk for heart attack and stroke far more than exposure to either factor alone, new research reveals. The results indicate that controlling air pollution may prove to be a powerful tool for preventing cardiovascular disease. Published in today's edition of the ...
-
21 Jun 2010: NIH-supported study finds novel pathway May open doors for new blood pressure treatments
Researchers have found that increasing certain proteins in the blood vessels of mice, relaxed the vessels, lowering the animal’s blood pressure. The study provides new avenues for research that may lead to new treatments for hypertension. "The paper demonstrates that cytochrome P450 plays an important role in the management of high blood pressure, a disease of enormous public health ...
-
Longeveron Publishes Peer Reviewed Study of Phase 1 Trial Results of Lomecel-B for Alzheimer’s Disease in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association
Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biopharma company developing cellular therapies for aging-related illnesses, chronic disorders, and other specific life-threatening conditions, announced the publication of results from a Phase 1 trial testing Lomecel-B on patients with mild Alzheimer’s disease (AD) in Alzheimer’s & Dementia®: The Journal of the ...
-
FDA Accepts Dupixent (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) 300 mg weekly to treat adult and pediatric patients aged 12 years and older with eosinophilic esophagitis (EoE), a chronic and progressive type 2 inflammatory ...
-
Dupixent (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has expanded the marketing authorization for Dupixent (dupilumab) in the European Union. Dupixent is now also approved in children aged 6 to 11 years as an add-on maintenance treatment for severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you